RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Oxytocin is a peptide hormone studied in social behavior, neurodevelopment and metabolism. Popular descriptions such as the “trust hormone” simplify a much more complicated evidence base. An early trust-game experiment generated interest, but later replication work did not support a meaningful increase in trusting behavior under the tested conditions. Larger clinical studies also failed to establish the proposed benefits for social functioning in autistic children or weight loss in adults with obesity. This article reviews these findings without treating research hypotheses as established uses. [1–4]
WHY STUDY CONTEXT MATTERS
Oxytocin research spans different biological questions. A laboratory task involving money transfers is not a measure of the quality of a relationship. A change in food intake during one test meal is not the same as sustained weight loss. A clinical questionnaire measures a defined outcome, not every aspect of a person's experience. Keeping these distinctions visible helps prevent a narrow result from becoming a broad claim.
The studies below examined specific clinical or experimental formulations. Their findings do not establish the identity, purity, safety or effectiveness of a separately sourced laboratory product.
FROM AN EARLY TRUST FINDING TO A LARGER REPLICATION
Kosfeld and colleagues reported in 2005 that oxytocin increased trusting behavior in an economic game. The study distinguished interpersonal trust from general willingness to take risks. It became an influential experiment in research on social behavior, but the endpoint remained behavior in that particular task. It did not show that oxytocin creates affection or improves relationships. [1]
A 2026 registered report by Kroll and colleagues tested the trust-game finding in 211 participants and pooled the data with another large replication, producing a combined sample of 532. Neither analysis found evidence of increased trusting behavior. The pooled equivalence analysis supported an effect within a small predefined range, while the new study's equivalence test alone was inconclusive. [2]
That distinction matters: the finding challenges a meaningful effect in the tested setting, rather than proving that oxytocin has no role in any social process. It also shows why an older positive result should be read alongside later attempts to reproduce it.
A LARGER TRIAL IN AUTISTIC CHILDREN AND ADOLESCENTS
Sikich and colleagues enrolled 290 children and adolescents aged three to seventeen in a 24-week randomized, placebo-controlled trial. The primary measure assessed social withdrawal and related social interaction. The oxytocin and placebo groups improved by similar amounts, with no statistically significant difference. Secondary measures of social and cognitive functioning generally did not differ either. [3]
Adverse-event incidence and severity were similar between groups during the study. That observation does not establish universal safety or validate a different product. The main efficacy finding was negative: the trial did not support a meaningful advantage for the tested intervention on its measured outcomes.
AN OBESITY TRIAL SEPARATED APPETITE FROM WEIGHT CHANGE
Plessow and colleagues randomized 61 adults with obesity to oxytocin or placebo for eight weeks. Body-weight change, the primary endpoint, did not differ between groups. The study also found no beneficial effects on the reported body-composition or resting-energy-expenditure measures. [4]
Calorie intake at an experimental meal was lower with oxytocin relative to placebo, but that secondary finding did not translate into weight loss over the study period. Reporting the meal result without the negative primary outcome would give readers an incomplete picture. The trial illustrates why appetite signals and sustained body-weight outcomes must be distinguished.
WHAT THIS EVIDENCE SUPPORTS
These studies support continued investigation of oxytocin biology while limiting broad behavioral and metabolic claims. They do not establish that a research peptide improves relationships, treats autism or produces weight loss. A useful summary considers replication, study size, the prespecified primary endpoint and the actual formulation tested. Scientific interest in a molecule is not equivalent to evidence supporting personal use.
REFERENCES
1. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature. 2005;435:673–676.
https://doi.org/10.1038/nature03701
2. Kroll CF, Schruers KRJ, Viechtbauer W, et al. Absence of a meaningful effect of intranasal oxytocin on trusting behavior: a registered report with pooled equivalence testing. Cortex. 2026;198:208–233.
https://doi.org/10.1016/j.cortex.2026.03.006
3. Sikich L, Kolevzon A, King BH, et al. Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder. New England Journal of Medicine. 2021;385:1462–1473.
https://doi.org/10.1056/NEJMoa2103583
4. Plessow F, Kerem L, Wronski ML, et al. Intranasal Oxytocin for Obesity. NEJM Evidence. 2024;3:EVIDoa2300349.
https://doi.org/10.1056/EVIDoa2300349